---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-065696"
form_type: "8-K"
ticker: "FENC"
cik: "0001211583"
company_name: "FENNEC PHARMACEUTICALS INC."
filed_at: "2026-05-22T20:05:17+00:00"
generated_at: "2026-05-22T21:18:43.157153+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Fennec announces new PEDMARK data at ASCO showing hearing loss reduction in pediatric/AYA patients

## Summary
- Phase 2/3 STS-J01 study met primary endpoint: hearing loss 16-24% vs 56-63% historical control.
- Randomized Phase 1 trial of cisplatin +/- PEDMARK for metastatic germ cell tumor opened at City of Hope.
- Retrospective case series (9 AYA patients) shows PEDMARK feasible and does not compromise cisplatin antitumor activity.
- Real-world data in 15 head & neck cancer adults: PEDMARK safe ≥6h after cisplatin, hearing preserved.
- Company expands evidence base for PEDMARK in broader populations beyond current pediatric approval.

## SEC filing metadata
- accession: 0001104659-26-065696
- form_type: 8-K
- ticker: FENC
- cik: 0001211583
- company_name: FENNEC PHARMACEUTICALS INC.
- filed_at: 2026-05-22T20:05:17+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1211583/000110465926065696/0001104659-26-065696-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1211583/000110465926065696/fencf-20260521x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-065696
- JSON: https://secwatch.observer/filing/0001104659-26-065696.json
- Plain text: https://secwatch.observer/filing/0001104659-26-065696.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.